Plain-English translation of NCT02738801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pulmonary fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers studied GLPG1690, an experimental medication, to see if it could help people with idiopathic pulmonary fibrosis — a disease where lung tissue gradually becomes scarred and makes it harder to breathe. About 23 participants received either the medication or a placebo (inactive pill) once daily for 12 weeks while doctors monitored their safety and how their lungs responded to the treatment.
Idiopathic pulmonary fibrosis is a serious condition with limited treatment options, and doctors are looking for new ways to slow the scarring and help patients breathe better. This early-stage trial investigated whether this medication might be safe and effective enough to study further.
Participants visited the study center about 7 times over 14 weeks — at the start, after 1, 2, 4, 8, and 12 weeks, plus a final follow-up visit 2 weeks later. At each visit, they underwent blood tests, lung function tests (spirometry), heart monitoring, and imaging scans, and they received either the medication or a placebo pill to take once daily at home. The trial was double-blind, meaning neither the participants nor the doctors knew who received the active medication versus the placebo.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Ukraine